Exclusive Summary

• Doxepin HCl 2mg Buccal Film under FDA approval with GMP certification, offering a clear differentiated dosage form advantage in the insomnia treatment space, with global markets open for distribution partnerships.
• The global insomnia burden is massive—approximately 700–1,000 million people worldwide suffer from chronic insomnia, with an adult prevalence of 10–30%, providing a large and well-defined target patient population.
• Low-dose doxepin is the only FDA-approved H1 antagonist for sleep maintenance insomnia with no addiction risk or scheduling concerns, and the buccal film format offers faster onset, improved bioavailability, and better patient adherence vs. conventional tablets.
• The buccal film formulation of doxepin is virtually absent from non-US markets, presenting a first-mover opportunity for distribution partners in Europe, Australia, Southeast Asia, Middle East, and Latin America.
• FDA GMP certification and completed US registration provide strong regulatory credibility, enabling partners to leverage existing CMC dossiers to accelerate registration in other markets and reduce compliance costs.